Skip to main content
Clinical Trials/NCT02301715
NCT02301715
Completed
Phase 1

Effects of Intranasal Oxytocin on Emotion Regulation to Stressful Interaction in Insecure Adolescents: a Study Protocol for a Double Blind Randomized Controlled Trial

Centre Hospitalier Universitaire de Besancon1 site in 1 country29 target enrollmentApril 29, 2014

Overview

Phase
Phase 1
Intervention
Oxytocin
Conditions
Emotion
Sponsor
Centre Hospitalier Universitaire de Besancon
Enrollment
29
Locations
1
Primary Endpoint
Conflict discussion
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to determine the effect of intranasal administration of OT on behavior and discourse of insecure adolescents during a disagreement (stressful situation) with parents.

Detailed Description

Emotional dysregulation and impaired attachment in adolescence are seen by clinical researchers as potential contributors to development of psychopathology. Recent evidence suggests that administration of intranasal OT may facilitate social interaction by attenuating the stress response to interpersonal conflict. However, to date there have been no studies investigating the effects of intranasal OT on parent-adolescent interaction and on neurophysiological emotional strategies in adolescence. To understand these mechanisms, this study examines the effects of OT on interpersonal emotional regulation in adolescent-parent stressful interaction, and on individual visual and physiological strategies in the visualizing attachment-related emotions pictures. The main objective will be to evaluate the effect of intranasal administration of OT on behavior and discourse of insecure adolescents during a disagreement (stressful situation) with one of his parents. Secondary is determine the effect of OT on visual exploration strategies and on the physiological responses (heart rate, galvanic skin response) on images elicited attachment-related emotions in insecure adolescents. In this randomized, double-blind, placebo-controlled, parallel designs, 60 healthy male adolescents classified with an insecure attachment will receive 24 IU of intranasal OT or placebo, 45 min before the experimental tasks. Adolescent will be invited with his/her parent to an experimental conflict discussion. The conflict session will be videotaped and coded for verbal and nonverbal interaction behavior (e.g., eye contact, nonverbal positive/negative behavior, and self-disclosure) with GPACS. Eye tracking and physiological responses will be recorded simultaneously and continuously during pictures viewing.

Registry
clinicaltrials.gov
Start Date
April 29, 2014
End Date
May 31, 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Have a clinical diagnosis of insecure attachment according to the Attachment Scale Interview
  • Male adolescents (and parents) enrolled in high school or college
  • Not hospitalized
  • Without current or past history of neurological or psychiatric illness, including substance abuse or dependence
  • Aged from 13 to 20 years
  • Speaking French
  • Have signed informed consent
  • Affiliation to a French social security

Exclusion Criteria

  • Intellectual deficit
  • Severe neurological symptoms
  • Known allergies to oxytocin or to preservatives in the nasal spray
  • Not speaking French
  • Visual disturbances
  • Chronic disease (liver failure, kidney failure, cardiovascular disease)
  • Antihypertensive therapy

Arms & Interventions

Oxytocin

24 IU Oxytocin, 3 puffs per nostril, each with 4 IU OXT, intranasal application 45 min prior to the experiment

Intervention: Oxytocin

Placebo

intranasal application, sodium chloride solution, 3 puffs per nostril, 45 min prior to the experiment

Intervention: Placebo

Outcomes

Primary Outcomes

Conflict discussion

Time Frame: 3 years

Adolescent will be invited with his/her parent to an experimental conflict discussion. The conflict session will be videotaped and coded for verbal and nonverbal interaction behavior (e.g., eye contact, nonverbal positive/negative behavior, and self-disclosure) with GPACS.Behavioral data will be collected during each of the study visits. Drug effect will be determined by comparing data obtained during placebo and oxytocin visits.

Secondary Outcomes

  • Visual patterns(3 years)

Study Sites (1)

Loading locations...

Similar Trials